Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence
Authors
Keywords
Infliximab, Etanercept, Adalimumab, Abciximab, Ranibizumab
Journal
BIODRUGS
Volume 30, Issue 6, Pages 489-523
Publisher
Springer Nature
Online
2016-11-02
DOI
10.1007/s40259-016-0199-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 489PFUNCTIONAL SIMILARITY ASSESSMENT RESULTS COMPARING BEVACIZUMAB TO BIOSIMILAR CANDIDATE ABP 215
- (2017) T.L. Born et al. ANNALS OF ONCOLOGY
- NCCN Biosimilars White Paper: Regulatory, Scientific, and Patient Safety Perspectives
- (2017) Andrew D. Zelenetz et al. Journal of the National Comprehensive Cancer Network
- I22. Biosimilars in Perspective: Regulation
- (2017) Bill Richardson RHEUMATOLOGY
- The changing landscape of biosimilars in rheumatology
- (2016) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Physicians prefer greater detail in the biosimilar label (SmPC) – Results of a survey across seven European countries
- (2016) Anna Hallersten et al. REGULATORY TOXICOLOGY AND PHARMACOLOGY
- Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
- (2016) Eduardo Mysler et al. RHEUMATOLOGY INTERNATIONAL
- Biosimilars: Rationale and current regulatory landscape
- (2016) Ewa Olech SEMINARS IN ARTHRITIS AND RHEUMATISM
- The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
- (2015) Ashok Jha et al. ADVANCES IN THERAPY
- Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases
- (2015) K. Papamichael et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- SAT0190 A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Patients with Active Rheumatoid Arthritis
- (2015) I. Jacobs et al. ANNALS OF THE RHEUMATIC DISEASES
- SP0192 “A Professional Career with A Rheumatic Disease”. Obstacles and Possibilities in Germany in Combination with A Personal Perspective
- (2015) G. Baseler ANNALS OF THE RHEUMATIC DISEASES
- SP0191 Measuring Quality of Life in Young Adults with Jia in Clinical Practice
- (2015) L. Haverman ANNALS OF THE RHEUMATIC DISEASES
- AB0420 Secondary Efficacy Outcomes from a Phase 3 Study Support Clinical Equivalence Between BOW015 and Infliximab in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses
- (2015) J. Kay et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0142 Immunogenicity Assessment of PF-06438179, A Potential Biosimilar to Infliximab, In Healthy Volunteers
- (2015) C. Udata et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0167 Relationship Between Pharmacokinetics and Anti-Drug Antibody Status of ABP 501, A Biosimilar Candidate to Adalimumab
- (2015) P. Kaur et al. ANNALS OF THE RHEUMATIC DISEASES
- FRI0107 Romanian Registry of Rheumatic Diseases: Efficacy and Safety of Biologic Therapy in Rheumatoid Arthritis
- (2015) C. Codreanu et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0151 Safety Profile of BOW015, A Biosimilar Infliximab, In Healthy Subjects and Patients with Active Rheumatoid Arthritis
- (2015) J. Kay et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0176 A Phase I Pharmacokinetic Study Comparing SB4, An Etanercept Biosimilar, and Etanercept Reference Product (Enbrel®) in Healthy Male Subjects: Table 1.
- (2015) Y.J. Lee et al. ANNALS OF THE RHEUMATIC DISEASES
- FRI0116 Pharmacokinetic Results from a Phase 1, Single-Centre, Double-Blind, Randomised, Single-Dose, Parallel Group Study Comparing 5 MG/KG IV Infusion of BOW015 and Reference Infliximab in Healthy Male Volunteers
- (2015) J. Lambert et al. ANNALS OF THE RHEUMATIC DISEASES
- A8.31 Authorised manufacturing changes of therapeutic monoclonal antibodies in EPAR documents
- (2015) Z Zrubka et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
- (2015) Jung-Yoon Choe et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
- (2015) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Case studies on clinical evaluation of biosimilar monoclonal antibody: Scientific considerations for regulatory approval
- (2015) Alex Kudrin et al. BIOLOGICALS
- Biosimilars advancements: Moving on to the future
- (2015) Lilian Rumi Tsuruta et al. BIOTECHNOLOGY PROGRESS
- Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis
- (2015) Kuttipurath Kandi Roshique et al. CLINICAL RHEUMATOLOGY
- Biosimilars in inflammatory bowel disease
- (2015) Fernando Gomollón CURRENT OPINION IN GASTROENTEROLOGY
- Current phase 1/2 research for neovascular age-related macular degeneration
- (2015) Paula E. Pecen et al. CURRENT OPINION IN OPHTHALMOLOGY
- Rheumatoid Arthritis: An Evolutionary Force in Biologics
- (2015) Philip Brown et al. CURRENT PHARMACEUTICAL DESIGN
- Biosimilar monoclonal antibodies: the scientific basis for extrapolation
- (2015) Huub Schellekens et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center
- (2015) Klaudia Farkas et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Early investigational TNF receptor antagonists for the treatment of ulcerative colitis
- (2015) Ian C Lawrance EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Biosimilar monoclonal antibodies in lymphoma: a critical appraisal
- (2015) Catherine Rioufol et al. Expert Review of Anticancer Therapy
- Tu1081 Preliminary Assessment of Efficacy and Safety of Switching Between Originator and Biosimilar Infliximab in Paediatric Crohn Disease Patients
- (2015) Jaroslaw Kierkus GASTROENTEROLOGY
- Mo1221 Comparative Assessments of PF-06438179, a Potential Biosimilar, and Infliximab in a Phase 1 Pharmacokinetic Study
- (2015) Donghua Yin et al. GASTROENTEROLOGY
- Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases
- (2015) Jürgen Braun et al. Immunotherapy
- P603. Efficacy of the new infliximab biomarker CT-P13 induction therapy on mucosal healing in ulcerative colitis patients
- (2015) Journal of Crohns & Colitis
- P137. 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn's Disease in UK, Italy and France
- (2015) Journal of Crohns & Colitis
- Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
- (2015) Yoon Suk Jung et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Regulatory considerations in oncologic biosimilar drug development
- (2015) Judith C Macdonald et al. mAbs
- Biosimilars in rheumatology: current perspectives and lessons learnt
- (2015) Thomas Dörner et al. Nature Reviews Rheumatology
- Inflammatory diseases: Integrating biosimilars into clinical practice
- (2015) Steven R. Feldman SEMINARS IN ARTHRITIS AND RHEUMATISM
- Biosimilar safety factors in clinical practice
- (2015) Walter Reinisch et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases
- (2015) Maria A.V. Willrich et al. Translational Research
- Canadian Public Reimbursement of Subsequent Entry Biologics (Sebs) / Biosimilars
- (2015) E.C. Siu et al. VALUE IN HEALTH
- Biosimilar Infliximab in inflammatory bowel diseases: First interim results from a prospective nationwide observational cohort
- (2015) K Gecse et al. ZEITSCHRIFT FUR GASTROENTEROLOGIE
- Development of biosimilars in an era of oncologic drug shortages
- (2015) Edward Li et al. Drug Design Development and Therapy
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- THU0104 Nonclinical Assessments Demonstrating the Similarity of the Proposed Biosimilar PF-05280586 and Rituximab
- (2014) S. I. Hurst et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to: ‘Cadmium the missing link between smoking and increased rheumatoid disease activity?’ by Cates and Hutchinson
- (2014) Caroline Ospelt et al. ANNALS OF THE RHEUMATIC DISEASES
- SP0027 Biosimilars: Potential Clinical Differences and European Regulatory Aspects
- (2014) J.V. Esplugues Mota ANNALS OF THE RHEUMATIC DISEASES
- FRI0264 A Randomized, Single-Blind, Single-Dose, Three-Arm, Parallel Group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of ABP 501 and Adalimumab: Results of Comparison with Adalimumab (EU)
- (2014) P. Kaur et al. ANNALS OF THE RHEUMATIC DISEASES
- FRI0301 A Phase I Pharmacokinetics TRIAL Comparing PF-06438179 (A Potential Biosimilar) and Infliximab in Healthy Volunteers (Reflections B537-01)
- (2014) C. Udata et al. ANNALS OF THE RHEUMATIC DISEASES
- SP0021 How to Optimize Doppler Settings for Fast Flow: Table 1.
- (2014) W.A. Schmidt ANNALS OF THE RHEUMATIC DISEASES
- OP0011 A Randomized, Double-Blind, Phase 3 Equivalence TRIAL Comparing the Etanercept Biosimilar, Hd203, with Enbrel®, in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA): Table 1.
- (2014) S.-C. Bae et al. ANNALS OF THE RHEUMATIC DISEASES
- AB0412 Preclinical PK and Safety Assessment of the Proposed Adalimumab Biosimilar Gp2017, Compared to Humira®:
- (2014) U. Kronthaler et al. ANNALS OF THE RHEUMATIC DISEASES
- OP0157 Clinical Response of Disease Activity, Disability and Mobility Indices in Relation to Anti-Drug Antibody in the Planetas
- (2014) W. Park et al. ANNALS OF THE RHEUMATIC DISEASES
- SP0086 Does Self Management save Costs in Health Care for People with RMDS?
- (2014) J. Dekker ANNALS OF THE RHEUMATIC DISEASES
- SP0005 Novel Imaging Markers for Oa: Costly or Effective?
- (2014) A.L. Tan ANNALS OF THE RHEUMATIC DISEASES
- Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis
- (2014) Jackie L Nam et al. ANNALS OF THE RHEUMATIC DISEASES
- A Review of CT-P13: An Infliximab Biosimilar
- (2014) Kate McKeage BIODRUGS
- Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)
- (2014) Susan Hurst et al. BIODRUGS
- The challenge of indication extrapolation for infliximab biosimilars
- (2014) Brian G. Feagan et al. BIOLOGICALS
- Biosimilars: Challenges and path forward
- (2014) Young Sik Kim et al. BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
- SYRCLE’s risk of bias tool for animal studies
- (2014) Carlijn R Hooijmans et al. BMC Medical Research Methodology
- A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)
- (2014) Donghua Yin et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers
- (2014) Liselijn A. B. Wisman et al. CLINICAL DRUG INVESTIGATION
- Poster Session I (PI-001-120) Displayed 7:30 am – 2:00 pm Attended 7:30 am – 9:00 am
- (2014) CLINICAL PHARMACOLOGY & THERAPEUTICS
- The global challenges and opportunities in the practice of rheumatology: White paper by the World Forum on Rheumatic and Musculoskeletal Diseases
- (2014) Mustafa Al Maini et al. CLINICAL RHEUMATOLOGY
- Evolution der Biologika in der Entzündungsmedizin – Biosimilars in Gastroenterologie, Rheumatologie und Dermatologie
- (2014) S. Schreiber et al. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT
- Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease
- (2014) Vito Annese et al. DIGESTIVE AND LIVER DISEASE
- Biosimilars: Are They Bioequivalent?
- (2014) Fernando Gomollón DIGESTIVE DISEASES
- Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series
- (2014) Yun-Seong Kang et al. DIGESTIVE DISEASES AND SCIENCES
- Biosimilars lining up to compete with Herceptin – opportunity knocks
- (2014) Kevin M Nelson et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer
- (2014) Marc Thill Expert Review of Anticancer Therapy
- The rise of biosimilars: potential benefits and drawbacks in rheumatoid arthritis
- (2014) Dae Hyun Yoo Expert Review of Clinical Immunology
- Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: Innovators, biosimilars, and intended copies
- (2014) Gilberto Castañeda-Hernández et al. JOINT BONE SPINE
- Biosimilar monoclonal antibodies: A Canadian regulatory perspective on the assessment of clinically relevant differences and indication extrapolation
- (2014) Bradley J. Scott et al. JOURNAL OF CLINICAL PHARMACOLOGY
- P565 An experience of anti-TNF biosimilar, CT-P13 use: clinical efficacy, safety and interchangeability in inflammatory bowel disease; a pilot study
- (2014) H.W. Kang et al. Journal of Crohns & Colitis
- O-31: Biologicals and biosimilars: Is similar the same?
- (2014) P.J. Declerck Journal of Crohns & Colitis
- Similar preclinical pharmacokinetics of the proposed biosimilar adalimumab GP2017 and originator adalimumab upon single and multiple administrations
- (2014) JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Physicochemical characterization of Remsima®
- (2014) Soon Kwan Jung et al. mAbs
- Etanercept biosimilars
- (2014) Valderilio F. Azevedo et al. RHEUMATOLOGY INTERNATIONAL
- Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280586 and Rituximab (MabThera®)
- (2014) Anne M. Ryan et al. TOXICOLOGIC PATHOLOGY
- Boosting Biosimilars Uptake in European Countries
- (2014) K.E. Young et al. VALUE IN HEALTH
- Budget Impact Analysis of Introducing Biosimilar Infliximab for the Treatment of Auto Immune Disorders In Five European Countries
- (2014) A. Jha et al. VALUE IN HEALTH
- Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn's Disease In Six Central Eastern European Countries
- (2014) V. Brodszky et al. VALUE IN HEALTH
- Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
- (2014) Aurelien Amiot et al. Therapeutic Advances in Gastroenterology
- Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
- (2013) Howard Lee AAPS Journal
- Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
- (2013) M. Rinaudo-Gaujous et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis
- (2013) Xingzhong Jin et al. ANNALS OF THE RHEUMATIC DISEASES
- Proposal for a new nomenclature of disease-modifying antirheumatic drugs: Table 1
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
- (2013) Dae Hyun Yoo et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
- (2013) Won Park et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
- (2013) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab
- (2013) Jan Visser et al. BIODRUGS
- Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab
- (2013) Hans C. Ebbers et al. DRUG DISCOVERY TODAY
- Clinical considerations for biosimilar antibodies
- (2013) Håkan Mellstedt EJC SUPPLEMENTS
- Rituximab biosimilars
- (2013) Edward M Vital et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- PHYSICOCHEMICAL PROPERTIES OF RITUXIMAB
- (2013) Luis F. Flores-Ortiz et al. JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
- Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
- (2013) Antonio da Silva et al. LEUKEMIA & LYMPHOMA
- Joint position statement by "Sociedad Española de Patología Digestiva" (Spanish Society of Gastroenterology) and "Sociedad Española de Farmacología" (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease
- (2013) Federico Argüelles-Arias et al. REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
- Biosimilar Safety Considerations in Clinical Practice
- (2013) Edwin Choy et al. SEMINARS IN ONCOLOGY
- Dispensation Channels of Anti-TNFs in Inflammatory Bowel Disease
- (2013) M. Thivolet et al. VALUE IN HEALTH
- Introduction of an Infliximab Biosimilar (CT-P13): A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland
- (2013) G. McCarthy et al. VALUE IN HEALTH
- Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerations
- (2013) Paul Chamberlain Bioanalysis
- Biosimilar, Biobetter, and Next Generation Antibody Characterization by Mass Spectrometry
- (2012) Alain Beck et al. ANALYTICAL CHEMISTRY
- Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry
- (2012) Christopher P Denton et al. ANNALS OF THE RHEUMATIC DISEASES
- The COX/prostaglandin-E2 pathway is critical for autocrine IL-17A production by TH17 cells upon synovial fibroblast interaction
- (2012) Sandra M J Paulissen et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative Pharmacokinetics of HD203, a Biosimilar of Etanercept, with Marketed Etanercept (Enbrel®)
- (2012) SoJeong Yi et al. BIODRUGS
- 320 Comparative Pharmacokinetics of Trastuzumab-US and Trastuzumab-EU and the Potential Biosimilar Trastuzumab-Pfizer in Male CD-1 Mice
- (2012) A.M. Ryan et al. EUROPEAN JOURNAL OF CANCER
- Expression and biological characterization of an anti-CD20 biosimilar candidate antibody
- (2012) Denise Dorvignit et al. mAbs
- Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects
- (2012) Bo Zhou et al. mAbs
- Setting the stage for biosimilar monoclonal antibodies
- (2012) Christian K Schneider et al. NATURE BIOTECHNOLOGY
- A non-innovator version of etanercept for treatment of arthritis
- (2011) Sunit Maity et al. BIOLOGICALS
- Evaluation of similar biotherapeutic products: Scientific and regulatory challenges
- (2011) Elwyn Griffiths et al. BIOLOGICALS
- CD20 antibodies: doing the time warp
- (2011) M. S. Cragg BLOOD
- Comparative Pharmacokinetics and Tolerability of Branded Etanercept (25 mg) and Its Biosimilar (25 mg): A Randomized, Open-Label, Single-Dose, Two-Sequence, Crossover Study in Healthy Korean Male Volunteers
- (2011) Namyi Gu et al. CLINICAL THERAPEUTICS
- Anti-TNF Treatment in Rheumatoid Arthritis
- (2011) Janina Geiler et al. CURRENT PHARMACEUTICAL DESIGN
- Biosimilars—why terminology matters
- (2011) Martina Weise et al. NATURE BIOTECHNOLOGY
- Biosimilars: a regulatory perspective from America
- (2011) Jonathan Kay ARTHRITIS RESEARCH & THERAPY
- Biosimilars: pharmacovigilance and risk management
- (2010) Leyre Zuñiga et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: A prospective, open-label, randomized, controlled study in Korean patients
- (2009) Dong-Hyun Choi et al. CLINICAL THERAPEUTICS
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
- (2009) Alessandro Liberati et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search